PTX 2.44% 4.2¢ prescient therapeutics limited

Ann: March 2020 Quarterly Update and Appendix 4C, page-4

  1. 10,322 Posts.
    lightbulb Created with Sketch. 1127
    "... the current pandemic has not had a material effect on the progress of Prescient’s clinical development programs to date. This is in part due to the importance of continuity of treatment for cancer patients."

    All still going well
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.